Endothelial dysfunction and ROS upregulation are key mechanisms in DES-induced neoatherosclerosis, highlighting antioxidant therapies as a potential preventive strategy.
Answers are grounded in this paper and cite their sources.
ROS and endothelial dysfunction merit study as neoatherosclerosis targets post-DES; leaves open clinical benefits of antioxidants.
In-stent neoatherosclerosis (NA), characterized by a relatively thin fibrous cap and large volume of yellow-lipid accumulation after drug-eluting stents (DES) implantation, has attracted much attention owing to its close relationship with late complications, such as revascularization and late stent thrombosis (ST). Accumulating evidence has demonstrated that more than one-third of patients with first-generation DES present with NA. Even in the advent of second-generation DES, NA still occurs. It is indicated that endothelial dysfunction induced by DES plays a critical role in neoatherosclerotic development. Upregulation of reactive oxygen species (ROS) induced by DES implantation significantly affects endothelial cells healing and functioning, therefore rendering NA formation. In light of the role of ROS in suppression of endothelial healing, combining antioxidant therapies with stenting technology may facilitate reestablishing a functioning endothelium to improve clinical outcome for patients with stenting.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: